Patent intelligence · US
US 10350162
Methods and compositions for oral administration of exenatide
Methods and compositions for oral administration of exenatide
Patent details — US 10350162
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 16, 2019
- Expiration
- Jul 11, 2039
- Applicant
- Oramed Ltd.
- Claims
- 11
- CPC classes
- A61K, A61K31/202, A61K31/22, A61K38/26
Quick answer
US 10350162 (Methods and compositions for oral administration of exenatide) is held by Oramed Ltd.. Status: granted. Granted Jul 16, 2019. Expires Jul 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Oramed Ltd.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/202, A61K31/22, A61K38/26, A61K38/56, A61K38/57
More from Oramed Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 11660327
Methods and compositions for oral administration of proteins
granted -
US 11395848
Methods and compositions for treating diabetes
granted -
US 10967051
Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof
granted -
US 10933022
Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
granted -
US 10881714
Methods and compositions for oral administration of proteins
granted -
US 10398762
Methods and compositions for treating diabetes
granted -
US 10342764
Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
granted
Frequently asked questions
What is US patent 10350162?
US 10350162 (Methods and compositions for oral administration of exenatide) is held by Oramed Ltd.. Status: granted. Granted Jul 16, 2019. Expires Jul 11, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10350162?
Oramed Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 10350162 expire?
Our index shows an expiration date of Jul 11, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.